OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (OTC Pink: AIMI) — an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19 — announced that as of today its common stock is trading under the ticker AIMI on the Pink Open Market and the Special Meeting on April 30, 2025, about a reverse split is still on. For additional information, refer to AIM’s Def ...

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Conference Call April 01, 2025 08:30 AM ET Company Participants Conference Call Operator - Operator/Introductory AnnouncerThomas Echols - Chief Executive OfficerConference Call Operator - Q&A Moderator Conference Call Participants Ed Wu - Analyst at Ascendant Capital Markets Conference Call Operator Hello and welcome to the AIM Immunotech fourth quarter and full year 2024 update conference call and webcast. As a brief reminder, all participants are currently in a l ...

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by collaborators AstraZeneca (pancreatic cancer) and Merck (advanced ovarian cancer) Company to host conference call and webcast on Tuesday, April 1st at 8:30 AM ET OCALA, Fla., March 27, 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) | Delaware | 52-0845822 | | --- | --- | | (State ...

On-demand video webcast now available Includes latest updates on pancreatic cancer and bird flu clinical trials OCALA, Fla., March 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced its participation in the Virtual Investor “Top 5 for ‘25” On-Demand Conference. As part of the event, AIM CEO Thomas K. Equels presented his top five reasons why he believes the investment community and industry colleagues should pay attention to the Company in 2025: Pr ...

Core Viewpoint - AIM ImmunoTech Inc. is initiating a clinical study to evaluate the combination of Ampligen and AstraZeneca's FluMist as an intranasal vaccine for influenza, particularly targeting avian influenza strains [1][3]. Group 1: Clinical Study Details - The planned study will follow a previous trial at the University of Alabama-Birmingham (UAB), which demonstrated that Ampligen significantly enhanced the immune response to seasonal influenza variants by over four-fold and induced cross-reactive secretory Immunoglobulin A against avian influenza strains H5N1, H7N9, and H7N3 [2]. - Paul Goepfert, MD, will serve as the Principal Investigator for the study, emphasizing the urgency due to the rising threat of avian influenza [3]. Group 2: Financial and Development Insights - AIM's CEO highlighted the potential for a cost-effective development of the vaccine combination, estimating that it would require no more than $10 million in development costs, significantly less than the billions potentially needed for new mRNA vaccines [4]. - The company is seeking funding for the study through industry or governmental grants, indicating a proactive approach to securing necessary resources [3]. Group 3: Company Background - AIM ImmunoTech Inc. is focused on developing therapeutics for various diseases, including cancers and viral infections, with Ampligen being a key investigational drug that acts as a TLR3 agonist [5].

OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it received notice from the NYSE American (the “American”) that the American has accepted the Company’s Plan to regain compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the American Company Guide. AIM has until June 11, 2026 to regain compliance with the NYSE’s Continued Listings Standards. AIM CEO Thomas K. Equels state ...

David Chemerow David Chemerow OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company’s Board of Directors (the “Board”) has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately. Mr. Chemerow brings more than 40 years of finance, accounting and operations leadership experience across multiple industries. He previously served as the Chief Financial Officer and T ...

Several subjects who received the highest dose in Phase 1 will also be included in Phase 2OCALA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been dosed in Phase 2 of the Phase 1b/2 clinical trial involving AIM’s Ampligen (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”). Several subjects from Pha ...

Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”)Watch the “What This Means” segment here OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced th ...